Liquidia (NASDAQ:LQDA) Price Target Raised to $23.00 at Wells Fargo & Company

Liquidia (NASDAQ:LQDA - Free Report) had its price target upped by Wells Fargo & Company from $20.00 to $23.00 in a research report released on Wednesday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

A number of other analysts have also issued reports on LQDA. Raymond James lifted their price objective on shares of Liquidia from $27.00 to $29.00 and gave the company a "strong-buy" rating in a research note on Friday, May 9th. Wall Street Zen upgraded shares of Liquidia from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Oppenheimer set a $13.00 price objective on shares of Liquidia and gave the company an "underperform" rating in a research note on Monday, May 19th. HC Wainwright lifted their price target on shares of Liquidia from $29.00 to $35.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, Needham & Company LLC restated a "buy" rating and issued a $25.00 price target on shares of Liquidia in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $26.67.

Liquidia Stock Up 0.2%

Shares of LQDA traded up $0.03 during mid-day trading on Wednesday, reaching $15.03. 1,879,582 shares of the stock traded hands, compared to its average volume of 1,088,318. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -9.22 and a beta of 0.24. The stock has a fifty day simple moving average of $14.71 and a 200 day simple moving average of $13.72. Liquidia has a 12-month low of $8.26 and a 12-month high of $19.41.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.03). The firm had revenue of $3.12 million for the quarter, compared to analysts' expectations of $3.23 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. On average, equities research analysts expect that Liquidia will post -1.51 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Jason Adair sold 1,856 shares of the business's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $25,185.92. Following the completion of the transaction, the insider now owns 184,304 shares of the company's stock, valued at approximately $2,501,005.28. The trade was a 1.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Rajeev Saggar sold 2,450 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $13.67, for a total transaction of $33,491.50. Following the transaction, the insider now directly owns 263,152 shares of the company's stock, valued at approximately $3,597,287.84. This trade represents a 0.92% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,138 shares of company stock valued at $450,233 over the last 90 days. 26.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Liquidia

Several institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers lifted its holdings in Liquidia by 6.0% in the first quarter. Rhumbline Advisers now owns 85,463 shares of the company's stock worth $1,261,000 after purchasing an additional 4,811 shares during the period. Bluefin Capital Management LLC acquired a new stake in Liquidia in the first quarter worth about $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Liquidia by 15.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company's stock worth $1,796,000 after purchasing an additional 16,022 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Liquidia by 10.7% in the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company's stock worth $12,703,000 after purchasing an additional 82,955 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Liquidia by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company's stock worth $556,000 after purchasing an additional 1,700 shares during the period. Institutional investors and hedge funds own 64.54% of the company's stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).